News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Newron Pharmaceuticals Says Phase II Study Show Painkiller Ralfinamide Improves Quality of Life
July 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Newron Pharmaceuticals SpA said its painkiller ralfinamide improved patients' quality of life compared to a placebo in phase II clinical tests.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Autoimmune disease
BMS, Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial
October 28, 2025
·
2 min read
·
Tristan Manalac
Autoimmune disease
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data
October 28, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data
October 27, 2025
·
2 min read
·
Dan Samorodnitsky
Special edition
Deep Dive: Chinese Biotech Innovation Can’t Be Stopped
October 27, 2025
·
3 min read
·
Annalee Armstrong
